Previous 10 | Next 10 |
WOBURN, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenue for the quarter and full y...
WOBURN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that it plans to participate in the following two dermato...
Biopharmaceutical company Biofrontera (BFRI) made its stock market debut on October 29, 2021, and hit its 52-week high of $14.63 on December 21, 2021. However, is it wise to buy the stock now despite the company being in its early stages of development? Let’s find out. Dermatologi...
WOBURN, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) , a biopharmaceutical company specializing in the commercialization of dermatological products, announced that through the exercise of outstanding warrants the majority ownership of Biofrontera AG w...
Gainers: Altamira Therapeutics (NASDAQ:CYTO) +37%. Takung Art (NYSE:TKAT) +34%. ShiftPixy (NASDAQ:PIXY) +37%. Pop Culture (NASDAQ:CPOP) +36%. Insignia Systems (NASDAQ:ISIG) +19%. Siyata (NASDAQ:SYTA) +16%. Calix (NYSE:CALX) +15%. WISeKey (NASDAQ:WKEY) +12%. Biofrontera (NASDAQ:BFRI) +13%. Law...
Gainers: MedAvail (NASDAQ:MDVL) +17%, Altamira Therapeutics (NASDAQ:CYTO) +17%, Orchard Therapeutics (NASDAQ:ORTX) +10%,Biofrontera (NASDAQ:BFRI) +9%, XORTX Therapeutics (NASDAQ:XRTX) +7%. Losers: Chembio Diagnostics (NASDAQ:CEMI) -16%, Gamida Cell (NAS...
Gainers: Insignia Systems (NASDAQ:ISIG) +83%.. Pop Culture (NASDAQ:CPOP) +24%. Regencell Bioscience RGC +20% BridgeBio Pharma BBIO +19%. Gamida Cell (NASDAQ:GMDA) +17%. ADDvantage Technologies (NASDAQ:AEY) +17%. Centogene (NASDAQ:CNTG) +14% Altamira Therapeu...
Gainers: Altamira Therapeutics (NASDAQ:CYTO) +21%, Regencell Bioscience (NASDAQ:RGC) +17%, BridgeBio Pharma BBIO +13%, ImmunityBio (NASDAQ:IBRX) +8%, BiondVax Pharmaceuticals BVXV +8%. Losers: Biofrontera (NASDAQ:BFRI) -21%, Microbot Medical (...
The healthcare sector has gained significant importance since the onset of the pandemic. Moreover, the industry is evolving with unique product launches and technological advancements. The healthcare sector has seen several IPOs this year. Healthcare companies 2seventy (TSVT), Regencell (RGC)...
Biofrontera is eyeing significant growth opportunities for its FDA-approved skin disease photodynamic therapy drug "Ameluz". Updates regarding several ongoing clinical studies for expanded label indications can be a catalyst for the stock in 2022. While Biofrontera maintains a pos...
News, Short Squeeze, Breakout and More Instantly...
The RhodoLED XL is approved by the FDA in combination with Ameluz ® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate severity on the face and scalp Biofrontera launched the commercial distribution of the Rhod...
Conference call begins at 10:00 a.m. Eastern time on Thursday, May 16, 2024 WOBURN, MA / ACCESSWIRE / May 15, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results f...
Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...